Skip to main content
Clinical Trials/ISRCTN15718519
ISRCTN15718519
Active, not recruiting
未知

Supporting uptake of risk-reducing medications and minimising treatment discontinuation: a process evaluation

Peter MacCallum Cancer Centre0 sites250 target enrollmentMay 2, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Prevention of breast cancer in clients at increased risk
Sponsor
Peter MacCallum Cancer Centre
Enrollment
250
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 2, 2024
End Date
October 30, 2026
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Peter MacCallum Cancer Centre

Eligibility Criteria

Inclusion Criteria

  • Eligibility Criteria for clients:
  • 1\. Female.
  • 2\. Age between 20 and 70 years old
  • 3\. Residual lifetime breast cancer risk of at least 20% or a 10\-year risk of at least 5%, or history of lobular carcinoma in situ (LCIS) or atypical hyperplasia, or previous thoracic irradiation
  • 4\. Does not require germline genetic testing to further clarify the risk
  • 5\. Does not carry a pathogenic variant in a high\-risk breast cancer predisposition gene and is not an untested 1st\-degree relative for carriers
  • 6\. No history of invasive breast cancer or ductal carcinoma in situ (DCIS)
  • 7\. No history of bilateral mastectomy
  • 8\. No prior or current use of breast cancer prevention medications
  • Eligibility for clinicians:

Exclusion Criteria

  • Not meeting the inclusion criteria

Outcomes

Primary Outcomes

Not specified

Similar Trials